Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, et al. Cognitive complaints in cancer survivors and expectations for support: results from a web–based survey. Cancer Med. 2019;8(5):2654–63.
Article PubMed PubMed Central Google Scholar
Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–40.
Article CAS PubMed Google Scholar
Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, et al. Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. J Clin Oncol. 2018;36(32):3231–9.
Article CAS PubMed Central Google Scholar
Lange M, Hardy-Léger I, Licaj I, Pistilli B, Rigal O, Le Fel J, et al. Cognitive impairment in patients with breast cancer before surgery: results from a CANTO cohort subgroup. Cancer Epidemiol Biomark Prev. 2020;29(9):1759–66.
Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080–6.
Lange M, Arbogast SL, Hardy-Léger I, Rigal O, Le Fel J, Pistilli B, et al. Cognitive change in breast cancer patients up to 2 years after diagnosis. JNCI J Nat Cancer Inst. 2022;115:322–31.
Oppegaard KR, Armstrong TS, Anguera JA, Kober KM, Kelly DL, Laister RC, et al. Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: a scoping review. Crit Rev Oncol Hematol déc. 2022;180:103822.
Schroyen G, Vissers J, Smeets A, Gillebert CR, Lemiere J, Sunaert S, et al. Blood and neuroimaging biomarkers of cognitive sequelae in breast cancer patients throughout chemotherapy: a systematic review. Transl Oncol. 2022;16:101297.
Article CAS PubMed Google Scholar
Van Der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: A cohort study. Breast Cancer Res. 2018;20(1):1–10.
Mandelblatt JS, Small BJ, Zhou X, Nakamura ZM, Cohen HJ, Ahles TA, et al. Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: the thinking and living with cancer study. Cancer. 2023;129(15):2409–21.
Article CAS PubMed Google Scholar
Janelsins MC, Lei L, Netherby-Winslow C, Kleckner AS, Kerns S, Gilmore N, et al. Relationships between cytokines and cognitive function from pre- to post-chemotherapy in patients with breast cancer. J Neuroimmunol. 2022;362:577769.
Article CAS PubMed Google Scholar
Ren X, St. Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017;117:267–73.
Article CAS PubMed Google Scholar
Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study†. Annal Oncol. 2015;26(7):1446–51.
Toh YL, Wang C, Ho HK, Chan A. Distinct cytokine profiles across trajectories of self-perceived cognitive impairment among early-stage breast cancer survivors. J Neuroimmunol. 2020;342:577196.
Article CAS PubMed Google Scholar
Tegeler C, O’Sullivan JL, Bucholtz N, Goldeck D, Pawelec G, Steinhagen-Thiessen E, et al. The inflammatory markers CRP, IL-6, and IL-10 are associated with cognitive function—data from the Berlin Aging Study II. Neurobiol Aging. 2016;38:112–7.
Article CAS PubMed Google Scholar
Belcher EK, Culakova E, Gilmore NJ, Hardy SJ, Kleckner AS, Kleckner IR, et al. Inflammation, attention, and processing speed in patients with breast cancer before and after chemotherapy. JNCI J Nat Cancer Inst. 2022;114(5):712–21.
Carroll JE, Nakamura ZM, Small BJ, Zhou X, Cohen HJ, Ahles TA, et al. Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors: the thinking and living with cancer study. J Clin Oncol. 2022;41:295–306.
Article PubMed PubMed Central Google Scholar
Vaz-Luis I, Cottu P, Mesleard C, Martin AL, Dumas A, Dauchy S, et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open. 2019;4(5):e000562.
Article PubMed PubMed Central Google Scholar
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
Article CAS PubMed Google Scholar
Benedict RH, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test–revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12(1):43–55.
Brickenkamp R, Zillmer E. The d2 Test of Attention. Seattle, WA: Hogrefe and Huber Publishers; 1998.
Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg. 1990;90(4):207–17.
Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Motor Skills. 1958;8(3):271–6.
Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643.
Wechsler D. WMS-III: Wechsler memory scale administration and scoring manual. Psychological Corporation. San Antonio, TX: Psychological Corporation. 1997.
Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.
Article CAS PubMed Google Scholar
Weis J, Tomaszewski KA, Hammerlid E, Ignacio Arraras J, Conroy T, Lanceley A, et al. International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12). JNCI J Nat Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw273.
Lyon DE, Cohen R, Chen H, Kelly DL, McCain NL, Starkweather A, et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol. 2016;301:74–82.
Article CAS PubMed PubMed Central Google Scholar
Kesler SR, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(SUPPL.):S109–16.
Article CAS PubMed Google Scholar
Henneghan AM, Palesh O, Harrison M, Kesler SR. Identifying cytokine predictors of cognitive functioning in breast cancer survivors up to 10 years post chemotherapy using machine learning. J Neuroimmunol. 2018;320:38–47.
Article CAS PubMed PubMed Central Google Scholar
Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y, et al. Long-term influence of adjuvant breast radiotherapy on cognitive function in breast cancer patients treated with conservation therapy. Int J Clin Oncol. 2019;24(1):68–77.
Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, et al. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2017;13(1):15–26.
Henneghan A, Wright ML, Bourne G, Sales AC. A cross-sectional exploration of cytokine-symptom networks in breast cancer survivors using network analysis. Can J Nurs Res. 2021;55(3):303–15.
留言 (0)